Strategic focus Target ADHD treatment portfolio with proprietary XR delivery platforms and potential to expand into other branded XR products; opportunities to partner or co-develop with larger pharma players seeking enhanced adherence therapies.

Acquisition tailwinds Recent merger activity with Aytu BioScience and related regulatory scrutiny suggest a period of organizational realignment and integration needs; potential for sales teams to engage on distribution, manufacturing scaling, or technology licensing during post-merger integration.

Manufacturing scale Mid-sized manufacturing footprint (51-200 employees) and funding runway indicate capacity to scale supply for additional XR formulations; opportunity to offer contract manufacturing, fill/finish services, or supply chain optimization to expand product launches.

Technology leverage Proprietary modified-release platforms combined with existing tech stack present a cross-sell opportunity to provide AI-enabled forecasting, serialization, and digital engagement tools to support commercial launches and market access.

Market readiness Multiple ADHD product launches already achieved; focus on expanding approved indications and alternative dosage forms (ODT or oral suspension) aligns with payer and patient access needs—sales strategy can target specialty pharmacies, durable medical equipment channels, and pediatric/adult ADHD segments.